Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker of AD, and our system can detect it years or decades before amyloid appears in the brain.
Location: United States, Massachusetts, Marlborough
Employees: 11-50
Total raised: $30M
Founded date: 2019
Investors 4
| Date | Name | Website |
| - | Aubrey Cap... | aubreycapi... |
| - | New York A... | newyorkang... |
| - | Maine Ange... | maineangel... |
| - | Inventages | inventages... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.10.2014 | Series C | $15M | - |
| 01.10.2014 | Series D | $15M | - |
Mentions in press and media 11
| Date | Title | Description |
| 03.05.2023 | AXEPTIO, A LEADER IN RESPECTFUL INTERNET USER CONSENT MANAGEMENT, HAS SECURED A 3.5 MILLION EURO INVESTMENT FROM ISAI, EVOLEM AND OVNI CAPITAL | Paris, May 3, 2023 - Since 2017, Axeptio has been developing a consent management platform aimed at rebuilding trust between internet users and brands. The platform has already been adopted by over 50,000 websites. As part of its internatio... |
| 23.12.2014 | Sick of immunotherapy? These biotech/medtech startups are doing something different. | ZipLine Medical Stapling up skin post-surgery is pretty much the norm to quickly seal up wounds, but it runs a risk of infection and injury from the extra damage to already sensitive skin. This Bay Area startup has a non-invasive, non-sutur... |
| 03.10.2014 | Startup aims to diagnose Alzheimer’s through simple eye test; raises $15M | “If binding increases over time, a positive diagnosis can be made, enabling clinicians to track the progress of the disease in patients by measuring levels of fluorescence – as well as potentially enabling doctors and pharmaceutical researc... |
| 01.10.2014 | Cognoptix Raises Over $15M in Series C | ACTON, MA, Emerging medical device company has closed the first tranche of a Series D round of financing totaling over $15 million. >> Click here for more funding data on Cognoptix >> To export Cognoptix funding data to PDF ... |
| 01.10.2014 | Cognoptix Closes $15M Series D Financing | Cognoptix, an Acton, MA-based emerging medical device company, closed the first tranche of a $15m Series D round of financing. The round was co-led by new investor Alopexx and existing investor Inventages Venture Capital, with participation... |
| 30.09.2014 | Cognoptix Raises over $15 Million to Fund Pivotal Clinical Trial and Final Product Development of Eye Test Designed to Identify Early-Stage Alzheimer's Disease | Over-subscribed Series D round co-led by Alopexx Enterprises LLC and Inventages “Our clinical trial results strongly suggest that the Cognoptix SAPPHIRE II eye test may alter the course of Alzheimer’s Disease by enabling early, reliable and... |
| 16.07.2013 | One to watch: Medical device company says eye test can diagnose Alzheimer’s | PET imaging is approved to detect these kinds of plaques in living patients, but a noninvasive, low-cost option is needed, said Dr. Carl Sadowsky, the Medical Director at Premiere Research Institute in West Palm Beach, Fla., and a principal... |
| - | Learn from a pro: Strategies to interest angels and VCs in a medical device startup | Paul Hartung, CEO of Cognoptix, Inc., a startup that has created a drug-device that could diagnose Alzheimer’s earlier in patients, is also the first person to have a syndicated angel deal in the Northeast. He’s raised more than $20 million... |
| - | One to watch: Medical device company says eye test can diagnose Alzheimer’s | Cognoptix, Inc. claims to have created a working, in-office, non-invasive eye-scan that detects Alzheimer’s earlier in patients. The SAPPHIRE II tracks a beta amyloid (“Ab”) signature in the eyes of potential Alzheimer’s patients. In a 10-s... |
| - | Startup aims to diagnose Alzheimer’s through simple eye test; raises $15M | Confirming an Alzheimer’s diagnosis today takes a multi-pronged approach: Doctors evaluate a patient’s mood and cognition, conduct basic neurological tests and perform brain imaging scans to gauge a patient’s likelihood of having the devast... |
Show more